var data={"title":"Pyrazinamide: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pyrazinamide: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6876?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=pyrazinamide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Pyrazinamide: Patient drug information&quot;</a> and <a href=\"topic.htm?path=pyrazinamide-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Pyrazinamide: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215773\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Tebrazid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215809\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antitubercular Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215775\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Tuberculosis, treatment (drug-susceptible):</b> Oral: <b>Note:</b> Always administer in combination with other antitubercular drugs (Nahid 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ATS/CDC/IDSA drug-sensitive tuberculosis guideline recommendations (Nahid 2016):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Dosing: </i>Doses should be based on <b>lean</b> body weight for patients within a normal weight range for their height (optimal dosing for obese patients has not been established) (Nahid 2016):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Once-daily therapy:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">40 to 55 kg: 1,000 mg once daily <b>Note:</b> The preferred frequency of administration is once daily; however, 5-days per week administration by directly-observed therapy (DOT) is an acceptable alternative (Nahid 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">56 to 75 kg: 1,500 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">76 to 90 kg: 2,000 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Three-times-weekly DOT:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">40 to 55 kg: 1,500 mg 3 times weekly</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">56 to75 kg: 2,500 mg 3 times weekly</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">76 to 90 kg: 3,000 mg 3 times weekly</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Twice-weekly DOT:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">40 to 55 kg: 2,000 mg twice weekly</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">56 to 75 kg: 3,000 mg twice weekly</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">76 to 90 kg: 4,000 mg twice weekly</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Regimens:</i> Treatment regimens for pulmonary tuberculosis and tuberculous meningitis consist of an initial 2-month phase of a 4-drug regimen that includes pyrazinamide, followed by a continuation phase of a 2-drug regimen (does not include pyrazinamide) of an additional 4 to 7 months for pulmonary tuberculosis and a continuation phase of an additional 7 to 10 months of a 2-drug regimen (does not include pyrazinamide) for tuberculous meningitis (optimal duration is not defined although continuation phase must continue for a minimum of 7 additional months). Adjunctive corticosteroid therapy (eg, dexamethasone, prednisolone) tapered over 6 to 8 weeks is also recommended for tuberculous meningitis; pyrazinamide frequency and dosing differs depending on treatment regimen selected; consult current drug-sensitive TB guidelines (Nahid 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215792\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=pyrazinamide-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Pyrazinamide: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Tuberculosis, active (drug-susceptible) (excludes meningitis): </b>Oral: <b>Note:</b> Always administer in combination with other antitubercular drugs (Nahid 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ATS/CDC/IDSA drug-susceptible tuberculosis guideline recommendations (Nahid 2016):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Dosing: </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Once-daily therapy: <b>Note: </b>The preferred frequency of administration is once daily; however, 5-days-per-week administration by directly observed therapy (DOT) is an acceptable alternative.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants, Children and Adolescents &lt;15 years and &le;40 kg: 30 to 40 mg/kg/dose once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents &lt;15 years and &gt;40 kg and Adolescents &ge;15 years: Refer to adult dosing</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Three-times-weekly DOT: <b>Note:</b> Although suggested dosing based on experience with twice-weekly regimen; experts suggest three-times-weekly regimens are more effective than twice-weekly DOT regimens; consult guidelines for specific information.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants, Children, and Adolescents &lt;15 years, weighing &le;40 kg: 50 mg/kg/dose administered 3 times weekly.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents &lt;15 years weighing &gt;40 kg or Adolescents &ge;15 years: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Regimens:</i> Treatment regimens for pulmonary tuberculosis consist of an initial 2-month phase of a 4-drug regimen that includes pyrazinamide, followed by a continuation phase of a 2-drug regimen (does not include pyrazinamide) of an additional 4 to 7 months. Pyrazinamide frequency and dosing differs depending on treatment regimen selected; consult current drug-sensitive TB guidelines (Nahid 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215777\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">CrCl &lt;30 mL/minute or receiving intermittent hemodialysis: Treatment of drug-susceptible TB: Adults: 25 to 35 mg/kg/dose 3 times per week administered after dialysis (do not administer daily) (Nahid 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22548558\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling. Use is contraindicated in cases of severe hepatic impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24520318\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215737\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215755\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Tuberculosis:</b> Adjunctive treatment of tuberculosis (TB) in combination with other antituberculosis agents</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215744\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Malaise</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Anorexia, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia, myalgia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Acne vulgaris, acquired blood coagulation disorder (anticoagulant effect), angioedema (rare), dysuria, fever, gout, hepatotoxicity, interstitial nephritis, porphyria, pruritus, sideroblastic anemia, skin photosensitivity, skin rash, thrombocytopenia, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215759\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to pyrazinamide or any component of the formulation; acute gout; severe hepatic damage</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215741\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatotoxicity: Dose-related hepatotoxicity ranging from transient ALT/AST elevations to jaundice, hepatitis and/or liver atrophy (rare) has occurred.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Alcoholism: Due to concerns for preexisting hepatic dysfunction, use with caution in patients with a history of alcoholism (even if ethanol consumption is discontinued during therapy).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Gout: May inhibit uric acid excretion; acute gouty attacks have been reported. Use with caution in patients with chronic gout; contraindicated with acute gout.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Porphyria: Use with caution in patients with porphyria.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal failure.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatotoxic agents: Use with caution in patients receiving concurrent medications associated with hepatotoxicity (particularly with rifampin). The 2-month rifampin-pyrazinamide regimen for the treatment of latent tuberculosis infection (LTBI) has been associated with severe and fatal liver injuries; incidence increased with pyrazinamide doses &gt;30 mg/kg/day. The Infectious Diseases Society of America and Centers for Disease Control and Prevention recommend that the 2-month rifampin-pyrazinamide regimen should not generally be used in patients with LTBI.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299964\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215746\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9836&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzbromarone: Pyrazinamide may diminish the therapeutic effect of Benzbromarone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Pyrazinamide may decrease the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: Pyrazinamide may enhance the hepatotoxic effect of RifAMPin. Severe (even fatal) liver injury has been reported in patients receiving these 2 drugs as a 2-month treatment regimen for latent TB infection. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215748\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13375012\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Due to the risk of tuberculosis to the fetus, treatment is recommended when the probability of maternal disease is moderate to high. Drug-susceptible TB guidelines recommend pyrazinamide as part of the initial treatment regimen; however, risks and benefits of use during pregnancy should be considered for each individual patient (Nahid 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13375013\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Pyrazinamide is excreted in breast milk; concentrations are less than maternal plasma concentration (Holdiness 1984). The amount of drug in breast milk is considered insufficient for the treatment of tuberculosis in breastfed infants. In the treatment of drug-susceptible tuberculosis, use of pyrazinamide is not a contraindication to breastfeeding in women deemed non-infectious who are treated with first-line agents (ie, pyrazinamide) (Nahid 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215750\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Periodic liver function tests, serum uric acid, sputum culture, chest x-ray 2-3 months into treatment and at completion</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215740\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Converted to pyrazinoic acid in susceptible strains of <i>Mycobacterium</i> which lowers the pH of the environment; exact mechanism of action has not been elucidated</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215758\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Bacteriostatic or bactericidal depending on drug's concentration at infection site </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Absorption: Well absorbed </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Widely into body tissues and fluids including liver, lung, and CSF </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Relative diffusion from blood into CSF: Adequate with or without inflammation (exceeds usual MICs) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CSF:blood level ratio: Inflamed meninges: 100% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 50% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 9 to 10 hours, prolonged with reduced renal or hepatic function</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Within 2 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (4% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215761\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Pyrazinamide Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $615.49</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215762\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Firizin (BD);</li>\n      <li>Macrozide (CO, LK);</li>\n      <li>Makrozyd (UA);</li>\n      <li>Mide (TW);</li>\n      <li>Neoprazin (BD);</li>\n      <li>Neotibi (ID);</li>\n      <li>P-Zide (BF, BJ, CI, ET, GH, GM, GN, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);</li>\n      <li>P.T.B. (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>P.Z.A. (TW);</li>\n      <li>Payzyna (UA);</li>\n      <li>Piraldina (AE, BG, BH, CY, EG, IL, IN, IQ, IR, IT, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Pirazinamida (PE);</li>\n      <li>Pirazinamida Prodes (ES);</li>\n      <li>Pirazinid (TR);</li>\n      <li>Pirilene (FR);</li>\n      <li>Pramide (PT);</li>\n      <li>Prazide (VN);</li>\n      <li>Pyrafat (DE, HK, MT);</li>\n      <li>Pyrafate (AT);</li>\n      <li>Pyramide (BD, TH);</li>\n      <li>Pyramin (PH);</li>\n      <li>Pyrazid (PK);</li>\n      <li>Pyrazinamid (HR, HU, PL);</li>\n      <li>Pyrazinamid Lederle (CH);</li>\n      <li>Pyrazinamid &rdquo;Dak&rdquo; (DK);</li>\n      <li>Pyrazinamid &rdquo;Medic&rdquo; (DK);</li>\n      <li>Pyrazinamide (TH);</li>\n      <li>Pyrazine (JO);</li>\n      <li>PZA (CH, QA, SA);</li>\n      <li>PZA-Ciba (IN, SG);</li>\n      <li>PZN-500 (ZW);</li>\n      <li>Rifater (MX);</li>\n      <li>Siramid (ID);</li>\n      <li>TBZet (ID);</li>\n      <li>Tebrazid (BE, CH, LU);</li>\n      <li>Tibicel (ID);</li>\n      <li>Tisamid (CZ, FI);</li>\n      <li>Tubranin (BD);</li>\n      <li>Zcure (PH);</li>\n      <li>Zinamide (AU, GB, NZ)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Thoracic Society, &ldquo;Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection,&rdquo; <i>MMWR Recomm Rep</i>, 2000, 49(RR-6):1-51.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ASHP. Standardize 4 Safety Initiative Compounded Oral Liquid Version 1.01. July 2017. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/s4s-ashp-oral-compound-liquids.ashx?la=en&amp;hash=4C2E4F370B665C028981B61F6210335AD5D0D1D6.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC) and American Thoracic Society, &ldquo;Update: Adverse Event Data and Revised American Thoracic Society/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection - United States, 2003,&rdquo; <i>MMWR</i>, 2003, 52(31):735-9. Available at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5231a4.htm. Last accessed February 16, 2005.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyrazinamide-drug-information/abstract-text/12904741/pubmed\" target=\"_blank\" id=\"12904741\">12904741</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Combs DL, O'Brien RJ, and Geiter LJ, &ldquo;USPHS Tuberculosis Short-Course Chemotherapy Trial 21: Effectiveness, Toxicity, and Acceptability: The Report of Final Results,&rdquo; <i>Ann Intern Med</i>, 1990, 112(6):397-406.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Davidson PT and Le HQ, &ldquo;Drug Treatment of Tuberculosis - 1992,&rdquo; <i>Drugs</i>, 1992, 43(5):651-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyrazinamide-drug-information/abstract-text/1379145/pubmed\" target=\"_blank\" id=\"1379145\">1379145</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. November 2013. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. October 2014. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed November 12, 2014</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Havlir DV and Barnes PF, &ldquo;Tuberculosis in Patients With Human Immunodeficiency Virus Infection,&rdquo; <i>N Engl J Med</i>, 1999, 340(5):367-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyrazinamide-drug-information/abstract-text/9929528/pubmed\" target=\"_blank\" id=\"9929528\">9929528</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Herlevsen P, Nielsen C, and Pedersen JT, &ldquo;Convulsions After Treatment With Pyrazinamide,&rdquo; <i>Tubercle</i>, 1987, 68(2):145-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyrazinamide-drug-information/abstract-text/3499016/pubmed\" target=\"_blank\" id=\"3499016\">3499016</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Holdiness MR, &quot;Antituberculosis Drugs and Breast-Feeding,&quot; <i>Arch Intern Med</i>, 1984, 144(9):1888.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyrazinamide-drug-information/abstract-text/6548112/pubmed\" target=\"_blank\" id=\"6548112\">6548112</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lacroix C, Hoang TP, Nouveau J, et al, &ldquo;Pharmacokinetics of Pyrazinamide and Its Metabolites in Healthy Subjects,&rdquo; <i>Eur J Clin Pharmacol</i>, 1989, 36(4):395-400.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyrazinamide-drug-information/abstract-text/2737233/pubmed\" target=\"_blank\" id=\"2737233\">2737233</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. <i>Clin Infect Dis</i>. 2016;63(7):e147-e195. doi: 10.1093/cid/ciw376.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyrazinamide-drug-information/abstract-text/27516382/pubmed\" target=\"_blank\" id=\"27516382\">27516382</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Starke JR and Correa AG, &ldquo;Management of Mycobacterial Infection and Disease in Children,&rdquo; <i>Pediatr Infect Dis J</i>, 1995, 14(6):455-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyrazinamide-drug-information/abstract-text/7667049/pubmed\" target=\"_blank\" id=\"7667049\">7667049</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Treatment of Latent Tuberculosis Infection (LTBI), Last Updated: April 8, 2004.&rdquo; Available at <a href=\"http://www.cdc.gov/nchstp/tb/pubs/tbfactsheets/250110.htm\" target=\"_blank\">http://www.cdc.gov/nchstp/tb/pubs/tbfactsheets/250110.htm</a>. Last accessed February 16, 2005.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9836 Version 107.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F215773\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F215809\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F215775\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F215792\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F215777\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22548558\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F24520318\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F215737\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F215755\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F215744\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F215759\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F215741\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299964\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F215746\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F215748\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13375012\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F13375013\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F215750\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F215740\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F215758\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F215761\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F215762\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9836|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=pyrazinamide-patient-drug-information\" class=\"drug drug_patient\">Pyrazinamide: Patient drug information</a></li><li><a href=\"topic.htm?path=pyrazinamide-pediatric-drug-information\" class=\"drug drug_pediatric\">Pyrazinamide: Pediatric drug information</a></li></ul></div></div>","javascript":null}